US 12005052
Topical roflumilast formulation having improved delivery and plasma half-life
granted A61KA61K31/44A61K45/06
Quick answer
US patent 12005052 (Topical roflumilast formulation having improved delivery and plasma half-life) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/06, A61K47/10